Log In
BCIQ
Print this Print this
 

TSR-022

  Manage Alerts
Collapse Summary General Information
Company AnaptysBio Inc.
DescriptionAnti-TIM3 mAb
Molecular Target T cell immunoglobulin and mucin domain 3 (TIM3) (HAVCR2)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentIND
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors
Regulatory Designation
PartnerTesaro Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today